[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361549-105":59,"doc-detail-361549-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","quantitative-global-proteomics-of-formalin-fixed-paraffin-embedded-tumors-identifies-dimethylated-g3bp1-at-arginine-460-as-a-robust-pharmacodynamic-biomarker","Quantitative Global Proteomics of Formalin-Fixed Paraffin-Embedded Tumors Identifies Dimethylated G3BP1 at Arginine 460 as a Robust Pharmacodynamic Biomarker","","MTA-cooperative inhibition of protein arginine methyltransferase 5 (PRMT5) is synthetic lethal with methylthioadenosine phosphorylase (MTAP)-deficient cancers. PRMT5 activity is commonly assessed by symmetric dimethylarginine (SDMA) on substrates, yet total-SDMA assays lack substrate specificity. This study identifies DMA peptides as clinical pharmacodynamic biomarkers for PRMT5 inhibition in formalin-fixed paraffin-embedded solid tumors using DIA-MS global proteomics without DMA enrichment, evaluating 145 peptides in AZD3470-treated xenografts. G3BP1(R460) dimethylation is the primary dose-correlated PD biomarker with robust quantitative detection.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/quantitative-global-proteomics-of-formalin-fixed-paraffin-embedded-tumors-identifies-dimethylated-g3bp1-at-arginine-460-as-a-robust-pharmacodynamic-biomarker/361549/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/quantitative-global-proteomics-of-formalin-fixed-paraffin-embedded-tumors-identifies-dimethylated-g3bp1-at-arginine-460-as-a-robust-pharmacodynamic-biomarker/361549.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PRMT5 activity linked to MTAP-deficient cancer?","Question",{"text":112,"@type":113},"MTA-cooperative PRMT5 inhibition is synthetic lethal with MTAP-deficient cancers because methylthioadenosine partially inhibits PRMT5, increasing vulnerability to PRMT5 inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitation exists in conventional SDMA assays for PRMT5 inhibition?",{"text":117,"@type":113},"Conventional approaches that measure total SDMA across proteins are not specific to individual PRMT5 substrates, which can reduce selectivity and sensitivity.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biomarker was identified for PRMT5 inhibition and how was it validated?",{"text":121,"@type":113},"Arginine dimethylation of G3BP1 at residue R460 (G3BP1(R460)) was identified as the primary PD biomarker due to high abundance and a significant post-treatment reduction correlated with dose, detected with DIA-MS quantitative performance and reproducibility.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361549,1790205407,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/jpr](pubs.acs.org/jpr)  Article   \nQuantitative Global Proteomics of Formalin-Fixed ParaffinEmbedded Tumors Identifies Dimethylated G3BP1 at Arginine 460 as a Robust Pharmacodynamic Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition  \nAnqi Tu, Elizabeth J Wiseman, Steve M Sweet, Jelena Urosevic, Joanna Loizou, Alan Barnicle, Christopher Richardson, Sudhanshu Abhishek, David C Chain, Yeoun Jin Kim,  \nand Andrew G Chambers *  \n Cite This: J. Proteome Res. 2026, 25, 3586−3594  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: MTA-cooperative inhibition of protein arginine methyltransferase 5 (PRMT5) is synthetic lethal with methylthioadenosine phosphorylase (MTAP)-deficient cancers. PRMT5 ′s enzymatic activity can be assessed by measuring symmetric dimethylarginine (SDMA) modification levels of protein substrates. However, conventional assays that attempt to measure total SDMA levels lack the specificity to measure individual PRMT5 substrates, and thus potentially reduce selectivity and sensitivity. This study aims to identify and characterize specific DMA peptides that can serve as clinical pharmacodynamic (PD) biomarkers for PRMT5 inhibition in formalin-fixed paraffin-embedded solid tumors, leveraging data-independent acquisition-mass spectrometry (DIA-MS)-based global proteomics without additional DMA enrichment. We evaluated 145 DMA peptides in xenograft models treated by a novel MTAP-selective PRMT5 inhibitor, AZD3470. Arginine dimethylation of G3BP1 at residue R460 (G3BP1(R460)) was identified as the primary PD biomarker for PRMT5 inhibition due to its high abundance and significant post-treatment reduction that correlated with dose. The global proteomics assay with a limit of detection/quantification characterized the quantitative performance and allowed for confident detection of G3BP1(R460). Using this quantitative assay, more than 90% reduction in G3BP1(R460) modification at 100 mg/kg was reproducibly detected in MTAP-null xenograft models. Our findings suggested that the DIA-MS proteomics assay can provide high specificity and sensitivity in the detection of PRMT5 inhibition.  \nKEYWORDS: PRMT5 inhibition, MTAP-deficient cancer, arginine dimethylation, DIA-MS proteomics, pharmacodynamic biomarker discovery  \n■ INTRODUCTION  \nProtein arginine methyltransferases (PRMTs) methylate protein arginine residues and thus play pivotal roles in regulating a variety of critical cellular processes, such as gene expression, signal transduction, RNA splicing, and DNA repair. 1−3 PRMTs can be categorized into three major types. Type I PRMTs catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine (ADMA), Type II PRMTs produce MMA and symmetric dimethylarginine (SDMA), and Type III PRMT (PRMT7) only generates MMA.4 PRMT5 is a member of the Type II PRMT group, of which overexpression in a variety of cancer types is often associated with poor prognosis.5−8 This relates to the role of PRMT5 in cell proliferation and survival through histone and  \nnonhistone modifications and epigenetic regulation, which may activate oncogenes and/or suppress immunity.9  \nPRMT5 inhibitors developed as anticancer agents are being actively investigated in preclinical and clinical studies, some of which have achieved promising preliminary clinical efficacy.10 Second-generation PRMT5 inhibitors specifically target methylthioadenosine phosphorylase (MTAP)-deficient cancer  \n\n| Received: February 3, 2026\u003Cbr>Revised: May 7, 2026\u003Cbr>Accepted: June 11, 2026\u003Cbr>Published: June 19, 2026 | |\n| --- | --- |\n\n© 2026 American Chemical Society  \n3586  \n[https://doi.org/10.1021/acs.jproteome.6c001](https://doi.org/10.1021/acs.jproteome.6c001)12  \nJ. Proteome Res. 2026, 25, 3586−3594  \ncells and demonstrate an ","cbCairUSxT5zSozN","https://ap.wps.com/l/cbCairUSxT5zSozN","pdf",3787796,"English","# ABSTRACT\n## KEYWORDS\n# INTRODUCTION","[{\"question\":\"Why is PRMT5 activity linked to MTAP-deficient cancer?\",\"answer\":\"MTA-cooperative PRMT5 inhibition is synthetic lethal with MTAP-deficient cancers because methylthioadenosine partially inhibits PRMT5, increasing vulnerability to PRMT5 inhibitors.\"},{\"question\":\"What limitation exists in conventional SDMA assays for PRMT5 inhibition?\",\"answer\":\"Conventional approaches that measure total SDMA across proteins are not specific to individual PRMT5 substrates, which can reduce selectivity and sensitivity.\"},{\"question\":\"Which biomarker was identified for PRMT5 inhibition and how was it validated?\",\"answer\":\"Arginine dimethylation of G3BP1 at residue R460 (G3BP1(R460)) was identified as the primary PD biomarker due to high abundance and a significant post-treatment reduction correlated with dose, detected with DIA-MS quantitative performance and reproducibility.\"}]","Quantitative Global Proteomics of Formalin-Fixed Paraffin-Embedded Tumors Identifies Dimethylated G3BP1 at Arginine 460 as a Robust Pharmacodynamic Biomarker | PDF",1790144799,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0efb415fe7a401389154b7b64a57a14.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df1fa35cda8617541d199002e934fa25.webp",982,1295,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc3b9e3e5a8ed54753afaa87a959823d.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae93ea752ac326d3e43d1ec976f68433.webp",980,1292]